

MAKING STRIDES TOWARDS NEW TREATMENTS

ONE ENDPOINT AT A TIME

Alzheimer's disease (AD) studies are notoriously complex, long, and suffer high failure rates, but research is critical in the continued effort to identify disease-modifying treatments. Signant Health can apply decades of direct experience, deep expertise, and innovative clinical trial technologies within our SmartSignals™ platform to help researchers detect signal while increasing the quality and reliability of data generated.

IMPROVE CLINICIAN RATINGS & ENDPOINT RELIABILITY

Simplify clinician rating processes and improve data quality with preset workflows, edit checks, and automated scoring built into our Electronic Clinician Ratings solutions. Combine with one of Signant's data analytics solutions to effectively manage endpoint measure risk factors.

MONITOR AND MANAGE RISKS TO DATA QUALITY

Reliable and accurate data is the cornerstone to any successful clinical trial but especially vital in Alzheimer's studies which suffer extremely high failure rates. Signant provides numerous in-study data quality monitoring and

data analysis solutions to identify, correct, and prevent common issues such as errors, bias, or fraud.

SCORE SCALES TO SUCCESS

Our eCOA solution includes electronic versions of ADAS-Cog and MMSE, among other common COAs, and provides built-in internal logic and edit checks to improve accuracy and consistency of scoring. Further reduce errors with our Rater Training program to ensure raters correctly administer and score scales, improving reliability of your endpoint data.

ENGAGE AND RETAIN PATIENTS IN LONG-TERM FOLLOW UP STUDIES

Participating in clinical trials can be difficult for people living with

Alzheimer's. Signant's eConsent solutions simplify home-based consent, while our Patient Concierge engages and reminds participants and their caregivers during long-term follow up studies, improving retention in these critical phases.

SENSITIVE MEASURES INCREASE SIGNAL DETECTION

Help your study team collect accurate data using highly sensitive sensors and assessments to improve signal detection. ActiGraph integration with our eCOA solution automates collection of activity and sleep data, and our proprietary computerized Cognitive Assessments help researchers detect subtle cognitive function changes over time.

COMMON LIBRARY MEASURES USED IN ALZHEIMER'S CLINICAL TRIALS

- ADAS-COG
- MMSE
- CDR
- RBANS
- ADCS-ADL

ASK US FOR A COMPLETE LIST.

Signant's end-to-end suite of evidence generation solutions and accompanying Alzheimer's clinical science and medicine expertise reduce burdens for participants and study teams while generating more accurate, reliable data to improve the probability of study success.

SIGNANT'S ALZHEIMER'S DEMENTIA CLINICAL RESEARCH EXPERIENCE

Phases

I II III IV

56 Languages

2,500+ Sites

50 Countries

64,000 Patients

160 Trials

SMARTSIGNALS™ TRIAL SOLUTIONS

eCOA | ELECTRONIC CLINICIAN RATINGS | eCONSENT
PATIENT CONCIERGE | BLINDED DATA ANALYTICS | RATER TRAINING & QUALIFICATION

MEET THE EXPERTS

Our in-house team of clinical science and medicine experts, highly experienced in Alzheimer's disease and other neurological indications, support and guide your studies from launch to closeout.



DAVID MILLER, MD

Clinical Vice President

Dr. Miller provides leadership and guidance on dementia protocols at Signant. As an expert in geriatric psychiatry, his experience ranges from faculty positions at prominent universities to serving as Principal Investigator in several dementia trials. He is co-author on the updated ADCS ADAS-Cog administration and scoring manual.



BARBARA ENGER

Associate VP, Clinical Science

With over 30 years' experience as an advanced practice psychiatric nurse in psychiatric treatment practice areas, academic instruction, and psychiatric clinical trials, Barbara provides clinical expertise to global CNS trial rater training and data quality programs.



PASCAL GOETGHEBEUR

Clinical Principal Cognition

As an experienced CNS pharmacologist and behavioral scientist in the psychiatry and neurodegeneration fields, Pascal focuses on cognition with a strategic and innovative approach toward drug development and manages the clinical aspect of Signant's proprietary clinical cognitive assessment battery.

CONTACT US TO LEARN HOW SIGNANT HEALTH CAN SUPPORT YOUR NEXT STUDY.